The Postoperative Pain Management Market all set to carve a niche for itself by aiming to reach US$ 57.8 Bn from 2022 to 2031

The Postoperative Pain Management Market is likely to grow at an impertinent level shortly. Chabot's powered by machine learning is the transformation of the way interaction amongst patients happens. Machine learning is there to help radiologists to identify differences in the scans. This, in turn, helps them in diagnosing and detecting health issues, that too, at an early stage. This is the ongoing trend in the healthcare vertical and the status quo is expected to remain unchanged even going forward.

Rising prevalence of postoperative pain, emergence of potential treatment therapies, and development of novel drug delivery approaches are some of the many factors that are expected to drive the growth of the global postoperative pain management market. The market is currently valued at US$ 35.5 Bn, and is expected to witness steady growth during the forecast period at a CAGR of around 5% (2022-2031).

Postoperative pain may cause severe problems such as respiratory, cardiovascular, endocrine, and metabolic dysfunctions, and thus, postoperative pain management is necessary. Growing number of surgical procedures and increasing awareness about postoperative pain management are expected to act as key factors for market growth. According to the National Center for Health Statistics, out of the total surgical procedures, half need postoperative pain management, which provides a high opportunity for market players.

Want Insights To Postoperative Pain Management Market? Ask For Sample! https://www.persistencemarketresearch.com/samples/24259

All opioid-based postoperative pain management drugs have substantial adverse effects that are limiting their use. As per CDC, 56,064 people died due to prescription opioid overdose in 2021. Growing incidence of drug overdose and side effects related to postoperative pain management drugs are expected to stunt overall growth of the market to some extent. However, drug manufacturers are focusing on the development of non-opioid drugs with a novel drug delivery approach for extended-release of medications, which can provide relief from postoperative pain for a longer duration of time.

Company Profiles:

Teva Pharmaceutical Industries Ltd.
Egalet Corporation
GlaxoSmithKline Plc.
Novartis AG
Allergan plc
Mylan N.V.
Pfizer Inc.
Purdue Pharma L.P
Janssen Pharmaceuticals, Inc.
Endo International plc
Pacira Pharmaceuticals Inc.

Planning To Conclude Your Strategy On A Decisive Note In The Postoperative Pain Management Market? Glance Through The "Methodology" Implied! https://www.persistencemarketresearch.com/methodology/24259

Key Takeaways from Market Study

Owing to the efficacy of opioid drugs in providing intense pain relief, the opioids segment held more than 2/3 of the global market in 2021.

Oral route of administration accounted for 37% of the global market share in 2021.

Retail pharmacies and hospitals together as distribution channel partners held more than half of the global market share in 2021.

North America held nearly half of the global postoperative pain management market share in 2021.

"Surge in number of patients undergoing surgical procedures, rising prevalence of postoperative pain, increasing treatment rate of postoperative pain, and commercial availability of abuse-deterrent opioid drugs are expected to drive market growth over the decade," says a Persistence Market Research analyst.

How About Knowing The Product/Technology Driving The Postoperative Pain Management Market Before Investing Therein? Click The "Purchase Now" Button Of Our Postoperative Pain Management Market Report! https://www.persistencemarketresearch.com/checkout/24259

Who is Winning?

Various companies manufacturing postoperative pain management drugs are collaborating with different pharmaceutical companies for the development of non-opioid-based analgesics, and also with organizations for developing integrated approaches toward pain management, and the prevention of diversion of prescription opioid medications and the signs of potential abuse or addiction associated with opioid medications.

With the ongoing opioid epidemic in the U.S., all major manufacturers are also focusing on developing novel analgesic drugs for postoperative pain management.

For instance, in 2020, Haihe Pharmaceutical Co. Ltd. signed an agreement with 3D Biomedicine Science & Technology Co. Ltd. to outsource the China rights for its RMX-1001 and RMX-1002 non-opioid analgesics candidates.

Key market players are Teva Pharmaceutical Industries Ltd., Allergan plc, Pfizer Inc., Novartis AG, Mylan N.V., Purdue Pharma L.P, Pacira Pharmaceuticals Inc., Endo International plc, Egalet Corporation GlaxoSmithKline Plc, and Janssen Pharmaceuticals, Inc.

What Else is in the Report?

Persistence Market Research offers a unique perspective and actionable insights on the postoperative pain management market in its latest study, presenting a historical demand assessment of 2016 - 2021 and projections for 2022-2031, based on drug class (opioids, NSAIDs, local anesthetic, and acetaminophen), route of administration (injectable, oral, topical, transdermal, and others), and distribution channel (hospital pharmacies, retail pharmacies, drug stores, clinics, and others), across seven key regions of the world.

Access Related Reports-

Lateral Flow Assays Market: https://www.persistencemarketresearch.com/market-research/lateral-flow-assays-market.asp

Influenza Diagnostics Market: https://www.persistencemarketresearch.com/market-research/influenza-diagnostics-market.asp

Contact Us:

Persistence Market Research
Address - 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. - +1-646-568-7751
USA-Canada Toll-free - +1 800-961-0353
Sales - sales@persistencemarketresearch.com

About Us:

Persistence Market Research (PMR), as a 3rd-party research organization, does operate through an exclusive amalgamation of market research and data analytics for helping businesses ride high, irrespective of the turbulence faced on the account of financial/natural crunches.

This release was published on openPR.